Clinical Trials Regeneron’s antibody cocktail helps prevent and treat Covid-19 in Phase III studies 13 Apr 2021
Clinical Trials Regeneron’s antibody cocktail helps prevent and treat Covid-19 in Phase III studies 13 Apr 2021
06 Apr 2021 Comment LoA Update: AMO Pharma’s AMO-1 for PMS and epilepsy sees 13-point leap in regulatory potential following investigator-sponsored Phase II completion 06 Apr 2021
06 Apr 2021 Comment Provention’s success with T1D-delaying mAb will contend with field’s need to develop screening protocols and ensuing cumulative costs, experts say 06 Apr 2021
01 Apr 2021 Comment Lilly’s Phase II results in Alzheimer’s disease have most experts saying donanemab is done 01 Apr 2021
31 Mar 2021 Comment LoA Update: Teva’s extended-release risperidone for schizophrenia sees 5-point boost in regulatory potential following positive Phase III study 31 Mar 2021
29 Mar 2021 Comment Provention’s FDA AdCom for mAb to delay T1D likely to home in on safety profile but strong efficacy buoys regulatory prospects 29 Mar 2021
18 Mar 2021 Comment Ionis’ prekallikrein target for Phase IIa antisense asset stands on par with approved prophylactic drugs in HAE 18 Mar 2021
22 Feb 2021 Comment Investigator-sponsored Phase II/III for Pfizer’s sirolimus for Sturge-Weber Syndrome sees 15-point surge in FDA regulatory potential 22 Feb 2021
18 Feb 2021 Comment LoA Update: Evolve’s Phase III PlasmaCap IG for PIDD sees 11-point boost to FDA regulatory potential 18 Feb 2021
11 Feb 2021 Comment Trials of Covid-19 long-hauler therapies could repurpose endpoints from other disease studies but evolving definitions pose challenges, experts say 11 Feb 2021
08 Feb 2021 Comment Corbus’ investigator-sponsored Phase II lenabasum trial in SLE has randomised 96 of the targeted 100 patients, investigator says 08 Feb 2021
